Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Frexalimab (SAR441344) in Healthy Adults
NCT05845996Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS), systemic lupus erythematosus (SLE) and Sjögren's syndrome comparing Frexalimab with Placebo (2 arms). Primary endpoint: Number of participants with adverse event (AE) at Day 155. Started Nov 2018; status: completed.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)systemic lupus erythematosus (SLE)Sjögren's syndrome
Beyond the preview
Go deeper on NCT05845996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845996.